QuidelOrtho (QDEL) Stock Price, News & Analysis

Company Overview

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions. Key product families include QuidelOrtho’s Sofia and QuickVue point-of-care testing platforms, Savanna molecular diagnostics system, and Ortho’s VITROS analyzers, ORTHO VISION blood-bank systems and related reagents and consumables.

QuidelOrtho serves hospitals, clinical laboratories, physician offices, urgent-care centers, pharmacies, blood banks and public-health organizations. The company operates across North America, Europe, Asia-Pacific and other international markets, providing diagnostic products for settings ranging from decentralized point-of-care testing to large automated laboratories. Its business combines Quidel’s expertise in rapid and molecular diagnostics with Ortho’s longstanding presence in laboratory and transfusion medicine.

Key Stats

• Today's Range: $13.09 to $14.28
• 50-Day Range: $10.34 to $15.32
• 52-Week Range: $9.92 to $35.58
• Volume: 2.86 million shs
• Average Volume: 2.38 million shs
• Market Capitalization: $962.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.63
• Consensus Rating: Reduce

QuidelOrtho Stock Analysis - MarketRank™

QuidelOrtho scored higher than 34% of companies evaluated by MarketBeat, and ranked 630th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

QuidelOrtho has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for QuidelOrtho is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

QuidelOrtho has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 93.33%

Earnings Growth

Earnings for QuidelOrtho are expected to grow by 93.33% in the coming year, from $0.75 to $1.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of QuidelOrtho is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of QuidelOrtho is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

QuidelOrtho has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.16% of the float of QuidelOrtho has been sold short.

Short Interest Ratio / Days to Cover

QuidelOrtho has a short interest ratio ("days to cover") of 4.92.

Change versus previous month

Short interest in QuidelOrtho has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

QuidelOrtho does not currently pay a dividend.

Dividend Growth

QuidelOrtho does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.49

News Sentiment

QuidelOrtho has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for QuidelOrtho this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, QuidelOrtho insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.10% of the stock of QuidelOrtho is held by insiders.

Percentage Held by Institutions

99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:QDEL
• CIK: 1906324
• Web: www.quidelortho.com
• Phone: (858) 552-1100
• Fax: 858-453-4338
• Employees: 6,500
• Year Founded: 1979

Price Target and Rating

• Average Price Target for QuidelOrtho: $13.63
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: -2.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($15.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 9.68
• P/E Growth: N/A
• Net Income: -$1.13 billion
• Net Margins: -39.20%
• Pretax Margin: -38.52%
• Return on Equity: 4.88%
• Return on Assets: 1.63%

Debt

• Debt-to-Equity Ratio: 1.43
• Current Ratio: 1.39
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $2.67 billion
• Price / Sales: 0.36
• Cash Flow: $18.96 per share
• Price / Cash Flow: 0.74
• Book Value: $28.27 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 68,575,000
• Free Float: 67,821,000
• Market Cap: $962.11 million
• Optionable: Optionable
• Beta: 0.79